Table 2 Response to treatment
From: Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
Response, n (%) | KRAS-positive (n = 206) | KRAS-negative (n = 324) | P-value |
|---|---|---|---|
ORR | 41 (20) | 55 (17) | 0.39 |
DCR | 96 (47) | 134 (41) | 0.23 |
Best overall response | |||
CR | 2 (1) | 1 (<1) | |
PR | 39 (19) | 54 (17) | |
SD | 55 (27) | 79 (24) | |
PD | 88 (43) | 153 (47) | |
Death | 12 (5) | 30 (9) | |
Not determined | 10 (5) | 7 (2) | |
